JP4913321B2 - 徐放性医薬組成物 - Google Patents

徐放性医薬組成物 Download PDF

Info

Publication number
JP4913321B2
JP4913321B2 JP2003515226A JP2003515226A JP4913321B2 JP 4913321 B2 JP4913321 B2 JP 4913321B2 JP 2003515226 A JP2003515226 A JP 2003515226A JP 2003515226 A JP2003515226 A JP 2003515226A JP 4913321 B2 JP4913321 B2 JP 4913321B2
Authority
JP
Japan
Prior art keywords
tablet
sustained release
implant
pharmaceutically active
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003515226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004535473A5 (cg-RX-API-DMAC7.html
JP2004535473A (ja
Inventor
アール. マルティノッド,サージ
ブランドン,マルコム
Original Assignee
バーバック コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バーバック コーポレイション filed Critical バーバック コーポレイション
Publication of JP2004535473A publication Critical patent/JP2004535473A/ja
Publication of JP2004535473A5 publication Critical patent/JP2004535473A5/ja
Application granted granted Critical
Publication of JP4913321B2 publication Critical patent/JP4913321B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
JP2003515226A 2001-06-29 2002-07-01 徐放性医薬組成物 Expired - Fee Related JP4913321B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR6024A AUPR602401A0 (en) 2001-06-29 2001-06-29 Sustained release delivery system
AUPR6024 2001-06-29
PCT/AU2002/000866 WO2003009833A1 (en) 2001-06-29 2002-07-01 Sustained release delivery system

Publications (3)

Publication Number Publication Date
JP2004535473A JP2004535473A (ja) 2004-11-25
JP2004535473A5 JP2004535473A5 (cg-RX-API-DMAC7.html) 2005-10-27
JP4913321B2 true JP4913321B2 (ja) 2012-04-11

Family

ID=3829990

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003515226A Expired - Fee Related JP4913321B2 (ja) 2001-06-29 2002-07-01 徐放性医薬組成物

Country Status (9)

Country Link
US (1) US8197839B2 (cg-RX-API-DMAC7.html)
EP (1) EP1411905A4 (cg-RX-API-DMAC7.html)
JP (1) JP4913321B2 (cg-RX-API-DMAC7.html)
CN (1) CN1536988A (cg-RX-API-DMAC7.html)
AU (2) AUPR602401A0 (cg-RX-API-DMAC7.html)
BR (1) BR0210630A (cg-RX-API-DMAC7.html)
CA (1) CA2452075C (cg-RX-API-DMAC7.html)
NZ (1) NZ529858A (cg-RX-API-DMAC7.html)
WO (1) WO2003009833A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
NZ530550A (en) * 2001-09-11 2004-11-26 Smart Drug Systems Inc Preparation of sustained release pharmaceutical composition
PL1696822T3 (pl) * 2003-11-13 2010-08-31 Psivida Inc Wstrzykiwane implanty o opóźnionym wydzielaniu mające matrycę rdzenia i powłokę podatne na erozję biologiczną
BRPI0511694A (pt) * 2004-05-31 2008-01-08 Smart Drug Systems Inc composições de liberação controlada
ES2432556T3 (es) 2004-08-04 2013-12-04 Evonik Corporation Métodos para fabricar dispositivos de suministro y sus dispositivos
WO2007123511A2 (en) * 2006-03-24 2007-11-01 Infinity Pharmaceuticals, Inc. Dosing regimens for the treatment of cancer
US20090005869A1 (en) * 2006-12-15 2009-01-01 University Of Virginia Patent Foundation Device which Attaches into a Joint and Carries a Payload of Controlled Release Drugs and Related Method thereof
NZ552290A (en) * 2006-12-21 2009-05-31 Bomac Research Ltd Tablet fomulation
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
WO2009086451A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
JP2011522773A (ja) * 2007-12-27 2011-08-04 インフィニティ ファーマスーティカルズ、インク. 治療剤での癌の処置方法
US9005649B2 (en) 2009-07-14 2015-04-14 Board Of Regents, The University Of Texas System Methods for making controlled delivery devices having zero order kinetics
CA2769795C (en) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
ITTO20111188A1 (it) 2011-12-22 2013-06-23 Vhit Spa Pompa a cilindrata variabile e metodo di regolazione della sua cilindrata
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
FI20155779A7 (fi) * 2015-10-30 2017-05-01 Solani Therapeutics Ltd Ei-steroidaalisen anti-inflammatorisen lääkkeen hidastetusti vapautuva annostelu
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
CN111989068B (zh) 2018-05-24 2024-10-25 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
CN110559431B (zh) * 2019-10-11 2023-02-28 南京农业大学 一种巨型艾美耳球虫纳米亚单位疫苗及其制备方法和应用
JP2023509981A (ja) * 2020-01-10 2023-03-10 エキリーブル バイオファーマシューティカルズ べスローテン フェンノートシャップ アベルメクチンによる神経障害の治療
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
CN116687882A (zh) * 2023-07-06 2023-09-05 杭州高成生物营养技术有限公司 一种布洛芬缓释小丸及其制备方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6445318A (en) * 1987-05-08 1989-02-17 Syntex Inc Delivery system for administration control of lhrh analogue
WO1992007556A1 (en) * 1990-10-31 1992-05-14 Amgen Inc. Polyvinyl alcohol coated pellet of growth hormone
JPH04230621A (ja) * 1990-08-22 1992-08-19 Merck & Co Inc 生体侵食性インプラント
JPH04230210A (ja) * 1990-06-20 1992-08-19 Monsanto Co 被覆された動物用植込み物
JPH06321803A (ja) * 1993-05-17 1994-11-22 Kirin Brewery Co Ltd 水溶性ペプチドホルモンの徐放性製剤
WO1995017881A1 (en) * 1993-12-27 1995-07-06 Sumitomo Pharmaceuticals Company, Limited Controlled-release pharmaceutical preparation
JPH09225040A (ja) * 1996-02-23 1997-09-02 Dow Corning Fr Sa 制御された放出をする装置の製造方法
WO1999015166A1 (en) * 1997-09-23 1999-04-01 Pfizer Limited Parasiticidal formulations
EP0990450A2 (en) * 1998-09-30 2000-04-05 Ivy Animal Health, Inc. Pharmaceutical implants
WO2001034112A1 (en) * 1999-11-10 2001-05-17 Sumitomo Pharmaceuticals Company, Limited Sustained-release drug formulations for implantation
WO2001037811A1 (en) * 1999-11-22 2001-05-31 Akzo Nobel N.V. Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
JP2001199879A (ja) * 1999-11-10 2001-07-24 Sumitomo Pharmaceut Co Ltd 薬物放出製剤

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279996A (en) * 1962-08-28 1966-10-18 Jr David M Long Polysiloxane carrier for controlled release of drugs and other agents
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4331652A (en) * 1979-09-12 1982-05-25 Eli Lilly And Company Controlled release parasitic formulations and method
US4578075A (en) * 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
DE3681348D1 (de) * 1985-06-11 1991-10-17 Teijin Ltd Oral-arzneizubereitung mit retardwirkung.
SE444801B (sv) 1985-06-28 1986-05-12 Johan Magnus Ullman Fender
US4786501A (en) * 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
JPH01500899A (ja) * 1986-05-16 1989-03-30 ザ・ステイト・オブ・ビクトリア 生物適合性インプラント
US5342622A (en) * 1986-05-16 1994-08-30 The State Of Victoria Subdermal biocompatible implants
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
JPH0618958B2 (ja) * 1989-03-08 1994-03-16 株式会社クラレ 多層容器および包装体
ATE90203T1 (de) 1989-03-17 1993-06-15 Pitman Moore Inc Kontrollierte, verzoegerte wirkstofffreisetzung von makromolekularen proteinen.
ES2058923T3 (es) 1989-06-21 1994-11-01 Univ Brown Res Found Sistema para terapia neurologica.
JPH11508224A (ja) * 1990-08-09 1999-07-21 エンドコン・インコーポレーテッド 多重ドラッグデリバリーシステム
US5211951A (en) * 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
KR100210509B1 (ko) * 1996-01-10 1999-07-15 성재갑 지속성 동물 성장 호르몬 제형 및 이의 제조 방법
AUPP279698A0 (en) 1998-04-03 1998-04-30 Sunscape Developments Limited Sustained release formulation
WO2000003660A1 (en) 1998-07-17 2000-01-27 Skyepharma, Inc. Biodegradable compositions for the controlled release of encapsulated substances
WO2000013666A1 (en) 1998-09-05 2000-03-16 Seung Jin Lee Biodegradable particulate polymeric preparation and process for producing thereof
TWI246928B (en) * 1998-09-10 2006-01-11 Sumitomo Pharma Long time drug-sustained release preparation
AU6283299A (en) 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
CA2379909C (en) 1999-08-06 2011-01-04 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
JP4230621B2 (ja) 1999-08-12 2009-02-25 住友ゴム工業株式会社 空気入りタイヤ
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
JP4504122B2 (ja) 2004-07-02 2010-07-14 株式会社マキタ 生垣バリカン

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6445318A (en) * 1987-05-08 1989-02-17 Syntex Inc Delivery system for administration control of lhrh analogue
JPH04230210A (ja) * 1990-06-20 1992-08-19 Monsanto Co 被覆された動物用植込み物
JPH04230621A (ja) * 1990-08-22 1992-08-19 Merck & Co Inc 生体侵食性インプラント
WO1992007556A1 (en) * 1990-10-31 1992-05-14 Amgen Inc. Polyvinyl alcohol coated pellet of growth hormone
JPH06321803A (ja) * 1993-05-17 1994-11-22 Kirin Brewery Co Ltd 水溶性ペプチドホルモンの徐放性製剤
WO1995017881A1 (en) * 1993-12-27 1995-07-06 Sumitomo Pharmaceuticals Company, Limited Controlled-release pharmaceutical preparation
JPH09225040A (ja) * 1996-02-23 1997-09-02 Dow Corning Fr Sa 制御された放出をする装置の製造方法
WO1999015166A1 (en) * 1997-09-23 1999-04-01 Pfizer Limited Parasiticidal formulations
EP0990450A2 (en) * 1998-09-30 2000-04-05 Ivy Animal Health, Inc. Pharmaceutical implants
WO2001034112A1 (en) * 1999-11-10 2001-05-17 Sumitomo Pharmaceuticals Company, Limited Sustained-release drug formulations for implantation
JP2001199879A (ja) * 1999-11-10 2001-07-24 Sumitomo Pharmaceut Co Ltd 薬物放出製剤
WO2001037811A1 (en) * 1999-11-22 2001-05-31 Akzo Nobel N.V. Composition allowing predefined and controlled release of active ingredient, preparation thereof and use

Also Published As

Publication number Publication date
AU2002344686B2 (en) 2008-07-31
US20040247643A1 (en) 2004-12-09
EP1411905A4 (en) 2008-01-23
CA2452075C (en) 2012-08-14
NZ529858A (en) 2006-02-24
WO2003009833A1 (en) 2003-02-06
AUPR602401A0 (en) 2001-07-26
CA2452075A1 (en) 2003-02-06
US8197839B2 (en) 2012-06-12
CN1536988A (zh) 2004-10-13
BR0210630A (pt) 2004-07-27
EP1411905A1 (en) 2004-04-28
JP2004535473A (ja) 2004-11-25

Similar Documents

Publication Publication Date Title
AU2002344686B2 (en) Sustained release delivery system
JP4800570B2 (ja) 徐放性医薬組成物
AU2002344686A1 (en) Sustained release delivery system
JP2005505557A (ja) 持続放出医薬組成物の調製
AU2002344685A1 (en) Sustained release pharmaceutical composition
JP2013049705A (ja) 持続放出医薬組成物
JP2004535473A5 (cg-RX-API-DMAC7.html)
US20050063907A1 (en) Radioopaque sustained release pharmaceutical system
AU2003201410B2 (en) Sustained release pharmaceutical composition
AU2003201410A1 (en) Sustained release pharmaceutical composition
AU2002315568B2 (en) Preparation of sustained release pharmaceutical composition
AU2002366248A2 (en) Radioopaque sustained release pharmaceutical system
AU2002315568A1 (en) Preparation of sustained release pharmaceutical composition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050603

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20081212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090602

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101005

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111011

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111027

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111220

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120119

R150 Certificate of patent or registration of utility model

Ref document number: 4913321

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150127

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees